Caladrius Biosciences

Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]

Caladrius Biosciences
TypePublic
Nasdaq: CLBS
Russell Microcap Index component
IndustryBiopharmaceuticals
HeadquartersBasking Ridge, New Jersey[1],
United States
Key people
David J. Mazzo
(CEO)
Websitecaladrius.com

Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.[3]

In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics.[5]

Cardiovascular disease

In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction.[6]

The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients. [7]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.